Eltenac |CAS#72895-88-6 | COX inhibitor

MedKoo Cat#: 530021 | Name: Eltenac

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eltenac is a cyclooxygenase (COX) inhibitor potentially for the treatment of pain.

Chemical Structure

Eltenac

CAS#72895-88-6

Theoretical Analysis

MedKoo Cat#: 530021

Name: Eltenac

CAS#: 72895-88-6

Chemical Formula: C12H9Cl2NO2S

Exact Mass: 300.9700

Molecular Weight: 302.17

Elemental Analysis: C, 47.70; H, 3.00; Cl, 23.46; N, 4.64; O, 10.59; S, 10.61

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Eltenac; Telzenac; Eltenaco; Eltenacum; B78820; B 78820; B-78820; BY820; BY 820; BY-820

IUPAC/Chemical Name

4-(2,6-Dichloroanilino)-3-thiopheneacetic acid

InChi Key

AELILMBZWCGOSB-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H9Cl2NO2S/c13-8-2-1-3-9(14)12(8)15-10-6-18-5-7(10)4-11(16)17/h1-3,5-6,15H,4H2,(H,16,17)

SMILES Code

O=C(O)CC1=CSC=C1NC2=C(Cl)C=CC=C2Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 302.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Klein T, Dullweber F, Brehm C, Prinz W, Baudler M, Figala V, Herrmann M. Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo. Biochem Pharmacol. 2008 Sep 15;76(6):717-25. doi: 10.1016/j.bcp.2008.06.025. Epub 2008 Jul 12. PMID: 18674517. 2: Ottillinger B, Gömör B, Michel BA, Pavelka K, Beck W, Elsasser U. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 2001 Apr;9(3):273-80. doi: 10.1053/joca.2000.0385. PMID: 11300751. 3: Prügner W, Huber R, Lühmann R. Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects. J Vet Pharmacol Ther. 1991 Jun;14(2):193-9. doi: 10.1111/j.1365-2885.1991.tb00822.x. PMID: 1920607. 4: MacKay RJ, Daniels CA, Bleyaert HF, Bailey JE, Gillis KD, Merritt AM, Katz TL, Johnson JC, Thompson KC. Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31. doi: 10.1111/j.2042-3306.2000.tb05330.x. PMID: 11202378. 5: Hamm D, Turchi P, Johnson JC, Lockwood PW, Thompson KC, Katz T. Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis. Am J Vet Res. 1997 Mar;58(3):298-302. PMID: 9055978. 6: Sandelin J, Harilainen A, Crone H, Hamberg P, Forsskåhl B, Tamelander G. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol. 1997;26(4):287-92. doi: 10.3109/03009749709105318. PMID: 9310109. 7: Dyke TM, Sams RA, Thompson KG, Ashcraft SM. Pharmacokinetics of multiple-dose administration of eltenac in horses. Am J Vet Res. 1998 Nov;59(11):1447-50. PMID: 9829405. 8: Cuniberti B, Odore R, Barbero R, Cagnardi P, Badino P, Girardi C, Re G. In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood. Vet J. 2012 Mar;191(3):327-33. doi: 10.1016/j.tvjl.2011.03.016. Epub 2011 May 11. PMID: 21565533. 9: Häfner D, Ibrahim M, Wollin L, Germann PG. Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS). Exp Toxicol Pathol. 2003 Jul;55(1):59-68. doi: 10.1078/0940-2993-00295. PMID: 12940630. 10: Goodrich LR, Furr MO, Robertson JL, Warnick LD. A toxicity study of eltenac, a nonsteroidal anti-inflammatory drug, in horses. J Vet Pharmacol Ther. 1998 Feb;21(1):24-33. doi: 10.1046/j.1365-2885.1998.00813.x. PMID: 9507454. 11: Göktaş EF, Kabil E, Arıöz F. Quantification and validation of nine nonsteroidal anti-inflammatory drugs in equine urine using gas chromatography- mass spectrometry for doping control. Drug Test Anal. 2020 Aug;12(8):1065-1077. doi: 10.1002/dta.2864. Epub 2020 Jun 28. PMID: 32449838.